Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Christian Thiede, MD, Nona Shayegi, MD, Michael Kramer, Martin Bornhäuser, MD, Markus Schaich, MD, Johannes Schetelig, MD, Uwe Platzbecker, MD, Christoph Röllig, MD, Gerhard Ehninger, MD

Blood (2011) 118 (21): 1445.

https://doi.org/10.1182/blood.V118.21.1445.1445

Published: 2011

Journal Articles

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

Uwe Platzbecker, MD, Ulrich Schuler, Martin Bornhäuser, Michael Kramer, Markus Schaich, MD, Uta Oelschlagel, Brigitte Mohr, Mathias Hänel, Hannes Wandt, Thomas Wagner, Hermann Einsele, Stefan W. Krause, MD, Heinrich Bodenstein, Walter E. Aulitzky, Norbert Schmitz, Anthony D. Ho, Gerhard Ehninger, MD, Christoph Röllig, MD

Blood (2011) 118 (21): 765.

https://doi.org/10.1182/blood.V118.21.765.765

Published: 2011

Journal Articles

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

Friedrich Stöolzel, MD, Thomas Illmer, MD, Claudia Dill, Michael Kramer, Brigitte Mohr, Christian Thiede, MD, Uwe Platzbecker, MD, Johannes Schetelig, MD, Christoph Röllig, MD, Martin Bornhäuser, Gerhard Ehninger, MD, Markus Schaich, MD

Blood (2011) 118 (21): 935.

https://doi.org/10.1182/blood.V118.21.935.935

Published: 2011

Journal Articles

A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial

Blood (2011) 118 (21): 497.

https://doi.org/10.1182/blood.V118.21.497.497

Published: 2011

Journal Articles

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Blood (2011) 118 (21): 255.

https://doi.org/10.1182/blood.V118.21.255.255

Published: 2011

Journal Articles

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

Uwe Platzbecker, MD, Christina Ganster, Jürgen Neesen, Andrea Kuendgen, MD, Katharina Götze, Gesine Bug, Katayoon Shirneshan, Friederike Braulke, Christoph Röllig, MD, Ralph Naumann, MD, Eckhard Büssemaker, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, MD, Ulrich Germing, MD, Detlef Haase, Gerhard Ehninger, MD

Blood (2011) 118 (21): 3799.

https://doi.org/10.1182/blood.V118.21.3799.3799

Published: 2011

Journal Articles

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Stefan Knop, MD, Christian Langer, MD, Monika Engelhardt, MD, Lars O Muegge, MD, Albrecht Reichle, MD, Christoph Röllig, MD, Martin Gramatzki, MD, Wolf Roesler, MD, Max S Topp, MD, Carmen Wesemeier, MD, Bernd Hertenstein, MD, Isrid Sturm, MD, Tobias Dechow, MD, Martin Kortüm, MD, Marianne Sauerwein, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 1945.

https://doi.org/10.1182/blood.V116.21.1945.1945

Published: 2010

Journal Articles

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Utz O Krug, MD, Anja Koschmieder, Joachim Gerss, PhD, Hubert Serve, MD, Björn Steffen, MD, Gesine Bug, MD, Markus Schaich, MD, Christian Brandts, MD, Christoph Röllig, MD, Gerhard Ehninger, MD, Ulrich Duehrsen, MD, Richard Noppeney, MD, Wolfgang E. Berdel, MD, Steffen Koschmieder, MD, Carsten Müller-Tidow, MD

Blood (2010) 116 (21): 2180.

https://doi.org/10.1182/blood.V116.21.2180.2180

Published: 2010

NARROW

Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia

A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial

No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma – First Results of a Phase II Trial by the German DSMM Group

Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only